A collaborative development of a dengue vaccine candidate successful in preclinical study
(Institut Pasteur) In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies, BioNet-Asia (BNA), an innovative vaccine developer, and the research team led by Dr. Anavaj Sakuntabhai at the Functional Genetics of Infectious Diseases Unit, Institut Pasteur Paris France, (GFMI-IP), announce today the promising development of Nanotaxi ® formulated DNA vaccine to induce strong immune response against dengue virus, after successful preclinical study.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Biotechnology | Dengue Fever | France Health | Genetics | Infectious Diseases | International Medicine & Public Health | Nanotechnology | Study | Vaccines